BRAF and neoplasm: 32 confirms these observations as AZD treatment resulted in tumor regression in three of five patients with BRAF‐mutated (V600E or V600K) and low pAKT melanomas 32. Similarly, a better response and longer time to progression were observed with AZD in patients who had BRAF‐mutation tumors compared to patients with wild‐type BRAF 33.